+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 3Weeks +
FEMALE
ID07612267

Evaluation of Mirikizumab Levels in Breast Milk of Lactating Women Receiving Subcutaneous Mirikizumab for Approved Conditions

Led by Eli Lilly and Company · Updated on 2026-11-04

14

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to measure the levels of mirikizumab in the breast milk of women who are breastfeeding and receiving stable doses of mirikizumab for an approved medical condition. The study focuses on lactating participants and their breastfed infants to understand the drug concentration in milk during therapy. Participants will continue their prescribed mirikizumab treatment, which is given by subcutaneous injection as maintenance therapy every four weeks. The study involves monitoring the concentration of mirikizumab in breast milk over a dosing interval up to 28 days. Participants will be involved for up to 94 days, including screening and follow-up periods. During this time, researchers will collect breast milk samples to measure drug levels and assess infant safety by tracking infant weight. The study includes evaluations before dosing and throughout the 28-day period to understand drug exposure and effects on the breastfeeding infant.

CONDITIONS

Brief Title

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here